GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » EV-to-EBITDA

Novo Nordisk A/S (Novo Nordisk A/S) EV-to-EBITDA

: 33.11 (As of Today)
View and export this data going back to 1981. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Novo Nordisk A/S's enterprise value is $553,306 Mil. Novo Nordisk A/S's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $16,713 Mil. Therefore, Novo Nordisk A/S's EV-to-EBITDA for today is 33.11.

The historical rank and industry rank for Novo Nordisk A/S's EV-to-EBITDA or its related term are showing as below:

NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.03   Med: 18.12   Max: 35.01
Current: 33.11

During the past 13 years, the highest EV-to-EBITDA of Novo Nordisk A/S was 35.01. The lowest was 11.03. And the median was 18.12.

NVO's EV-to-EBITDA is ranked worse than
82.01% of 467 companies
in the Biotechnology industry
Industry Median: 9.63 vs NVO: 33.11

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-16), Novo Nordisk A/S's stock price is $123.83. Novo Nordisk A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.693. Therefore, Novo Nordisk A/S's PE Ratio for today is 45.98.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Novo Nordisk A/S EV-to-EBITDA Historical Data

The historical data trend for Novo Nordisk A/S's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.85 16.87 26.10 27.51 27.12

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.51 29.26 27.75 29.36 27.12

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's EV-to-EBITDA falls into.



Novo Nordisk A/S EV-to-EBITDA Calculation

Novo Nordisk A/S's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=553306.097/16713.048
=33.11

Novo Nordisk A/S's current Enterprise Value is $553,306 Mil.
Novo Nordisk A/S's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $16,713 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk A/S  (NYSE:NVO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Novo Nordisk A/S's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=123.83/2.693
=45.98

Novo Nordisk A/S's share price for today is $123.83.
Novo Nordisk A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.693.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Novo Nordisk A/S EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.